Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Acquired resistance inevitably develops, with the EGFR T790M mutation comprising approximately 55% of the mechanisms...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ther Adv Med Oncol
Main Authors: Liao, Bin-Chi, Griesing, Sebastian, Yang, James Chih-Hsin
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2019
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6878608/
https://ncbi.nlm.nih.gov/pubmed/31803256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919890286
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares